Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII

Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, S., Teh, P., Zhou, J., Chang, E. Y., von Drygalski, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735189/
https://www.ncbi.nlm.nih.gov/pubmed/31559096
http://dx.doi.org/10.1155/2019/9026121
_version_ 1783450307356786688
author Nguyen, S.
Teh, P.
Zhou, J.
Chang, E. Y.
von Drygalski, A.
author_facet Nguyen, S.
Teh, P.
Zhou, J.
Chang, E. Y.
von Drygalski, A.
author_sort Nguyen, S.
collection PubMed
description Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products.
format Online
Article
Text
id pubmed-6735189
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67351892019-09-26 Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII Nguyen, S. Teh, P. Zhou, J. Chang, E. Y. von Drygalski, A. Case Rep Hematol Case Report Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products. Hindawi 2019-08-28 /pmc/articles/PMC6735189/ /pubmed/31559096 http://dx.doi.org/10.1155/2019/9026121 Text en Copyright © 2019 S. Nguyen et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Nguyen, S.
Teh, P.
Zhou, J.
Chang, E. Y.
von Drygalski, A.
Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title_full Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title_fullStr Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title_full_unstemmed Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title_short Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
title_sort acquired hemophilia a (fviii deficiency) associated with papillary thyroid cancer: treatment with recombinant porcine fviii
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735189/
https://www.ncbi.nlm.nih.gov/pubmed/31559096
http://dx.doi.org/10.1155/2019/9026121
work_keys_str_mv AT nguyens acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii
AT tehp acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii
AT zhouj acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii
AT changey acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii
AT vondrygalskia acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii

Ejemplares similares